Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.363
Neutral
RSI(14)
40.038
Neutral
STOCH(KDJ)(9,3,3)
15.896
Sell
ATR(14)
2.345
Low Volatility
CCI(14)
-162.173
Sell
Williams %R
96.379
Oversold
TRIX(12,20)
0.402
Sell
StochRSI(14)
0.000
Oversold
Search
Harrow Inc
HROWAdd to Watchlist
38.893USD
+0.443+1.15%
Close 07-24 16:00（ET）Quotes delayed by 15 min
1.45BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.15%
5 Days
-16.63%
1 Month
-7.55%
6 Months
-11.26%
Year to Date
-20.63%
1 Year
+7.47%
Key Figures
42.300Open
42.300High
527.00Volume
LossP/E TTM
15.42P/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
38.450Prev. Close
38.110Low
597.00Turnover
LossP/E Static
50.50P/B
0.00%Div Yield TTM
-3.82%ROA
54.85052wk High
-0.00Volume Ratio
-17.48MNet Profit
37.27MShares
-0.3849EPS TTM
0.29Beta
-35.14%ROE
25.68052wk Low
10.90%Amplitude
61.18%Gross Margin
1.45BMarket Cap
-2.43Reward/Risk
3.54%Risk Rate
TradingKey Stock Score of Harrow Inc
Currency: USD Updated: 2026-07-24Key Insights
Harrow Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.57.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harrow Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Harrow Inc Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.15% year-on-year.
Fairly Valued
The company’s latest PE is -99.90, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.67M shares, increasing 1.39% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.60M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.11.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
65.571
Target Price
+56.57%
Upside Space
Harrow Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
8
analysts
Buy
Current Rating
65.571
Target Price
+56.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Harrow Inc
HROW
8
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
42.264
Sell
MA10
42.896
Sell
MA20
43.098
Sell
MA50
38.578
Buy
MA100
37.863
Buy
MA200
41.134
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Harrow Inc Info
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMullery (Frank)
Websitehttps://www.harrow.com/
Shareholders
Related Instruments
0.00%
+0.18%
+1.47%
-0.33%
+0.33%
0.00%
0.00%
+1.29%
+0.91%
+0.20%
+0.61%
+0.97%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%Popular Instruments
52475.200
+575.200 (+1.11%)
28487.700
+337.300 (+1.20%)
7470.700
+62.600 (+0.84%)
15109.000
+161.000 (+1.08%)
64856.000
+637.000 (+0.99%)
6357.200
+92.700 (+1.48%)
83.495
-6.548 (-7.27%)
333.800
+0.780 (+0.23%)
208.000
+1.160 (+0.56%)
4086.950
+34.600 (+0.85%)
FAQs
What is the current price of Harrow Inc (HROW)?
The current price of Harrow Inc (HROW) is 38.45.
What is the symbol of Harrow Inc?
The ticker symbol of Harrow Inc is HROW.
What is the 52-week high of Harrow Inc?
The 52-week high of Harrow Inc is 54.85.
What is the 52-week low of Harrow Inc?
The 52-week low of Harrow Inc is 25.68.
What is the market capitalization of Harrow Inc?
The market capitalization of Harrow Inc is 1.43B.
Is Harrow Inc (HROW) currently rated as Buy, Hold, or Sell?
According to analysts, Harrow Inc (HROW) has an overall rating of Buy, with a price target of 65.57.
What is the Earnings Per Share (EPS TTM) of Harrow Inc (HROW)?
The Earnings Per Share (EPS TTM) of Harrow Inc (HROW) is -0.14.